Cardiometabolic abnormalities and chronic kidney disease (CKD) are deeply intertwined, and each is independently associated with adverse outcomes. Medications primarily used to treat hypertension and diabetes (eg, angiotensin-converting enzyme inhibitors, sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists) can also reduce the risk of major adverse cardiovascular events and progression of CKD.1,2 In contrast, lipid-lowering therapy reduces risk of major cardiovascular events but does not seem to alter the course of CKD.